QURE - uniQure N.V.

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 501

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Matthew Craig Kapusta	CEO & Exec. Director	1.16M	N/A	1972
Mr. Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site	566.36k	N/A	1973
Mr. Pierre Caloz	Chief Operating Officer	951.1k	N/A	1972
Dr. Ricardo Dolmetsch Ph.D.	Pres of R&D	911.07k	N/A	1969
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	N/A	N/A	N/A
Dr. Jeannette Potts J.D., Ph.D.	Chief Legal & Compliance Officer	N/A	N/A	1962
Dr. Tamara Tugal Ph.D., MBA	Bus. Devel. Director	N/A	N/A	N/A
Ms. Erin Boyer	Chief People & Culture Office	N/A	N/A	N/A
Ms. Maria E. Cantor	Chief Corp. Affairs Officer	N/A	N/A	1968
Mr. Richard Porter Ph.D.	Chief Bus. Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate governance

uniQure N.V.’s ISS governance QualityScore as of 1 June 2023 is 3. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.